Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CSCI COSCIENS Biopharma	$3.48 -2.4%	$3.66	$1.96 ▼ $6.58	$11.01M	0.91	3,888 shs	1,491 shs
GANX Gain Therapeutics	$1.54 -0.6%	$1.68	$0.95 ▼ $3.19	$55.72M	0.1	232,088 shs	104,218 shs
GRCE Grace Therapeutics	$3.08 -6.1%	$3.07	$1.75 ▼ $4.97	$45.36M	0.72	73,476 shs	185,902 shs
HYPD Hyperion DeFi	$6.69 -5.0%	$8.98	$0.85 ▼ $75.18	$39.44M	2.42	767,143 shs	382,832 shs

10 Stocks Set to Soar in Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CSCI COSCIENS Biopharma	-0.69%	+1.02%	+1.16%	-3.44%	+347,599,900.00%
GANX Gain Therapeutics	-0.65%	+3.36%	-9.41%	-23.38%	+37.50%
GRCE Grace Therapeutics	-6.10%	+4.41%	-3.45%	+10.00%	+307,999,900.00%
HYPD Hyperion DeFi	-4.97%	+21.64%	-48.10%	+492.04%	-89.05%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CSCI COSCIENS Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GANX Gain Therapeutics	2.2172 of 5 stars	3.5	3.0	0.0	0.0	2.2	0.0	0.6
GRCE Grace Therapeutics	2.8291 of 5 stars	3.5	0.0	0.0	0.0	3.4	0.8	1.3
HYPD Hyperion DeFi	0.3596 of 5 stars	1.0	0.0	0.0	0.0	2.4	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CSCI COSCIENS Biopharma	0.00	N/A	N/A	N/A
GANX Gain Therapeutics	3.00	Buy	$7.80	406.49% Upside
GRCE Grace Therapeutics	3.00	Buy	$12.00	289.61% Upside
HYPD Hyperion DeFi	2.00	Hold	$2.00	-70.10% Downside

Current Analyst Ratings Breakdown

Latest CSCI, GANX, HYPD, and GRCE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	GANX Gain Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$7.00 ➝ $6.00
7/3/2025	GANX Gain Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
5/19/2025	GANX Gain Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CSCI COSCIENS Biopharma	$9.59M	1.14	N/A	N/A	$3.49 per share	1.00
GANX Gain Therapeutics	$50K	1,107.26	N/A	N/A	$0.10 per share	15.40
GRCE Grace Therapeutics	N/A	N/A	N/A	N/A	$4.60 per share	N/A
HYPD Hyperion DeFi	$60K	624.40	N/A	N/A	($695.52) per share	-0.01

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CSCI COSCIENS Biopharma	-$15.31M	-$5.80	N/A	∞	N/A	-194.50%	-101.01%	-43.90%	N/A
GANX Gain Therapeutics	-$20.41M	-$0.63	N/A	N/A	N/A	N/A	-289.10%	-155.11%	N/A
GRCE Grace Therapeutics	-$9.57M	-$0.86	N/A	N/A	N/A	N/A	-20.36%	-18.09%	N/A
HYPD Hyperion DeFi	-$49.82M	-$58.40	N/A	N/A	N/A	-62,238.41%	N/A	-369.98%	N/A

Latest CSCI, GANX, HYPD, and GRCE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CSCI COSCIENS Biopharma	N/A	-$0.85	N/A	-$0.85	N/A	N/A
8/13/2025	Q2 2025	HYPD Hyperion DeFi	N/A	-$2.50	N/A	-$2.50	N/A	N/A
8/12/2025	Q2 2025	GANX Gain Therapeutics	-$0.17	-$0.19	-$0.02	-$0.19	N/A	N/A
8/12/2025	Q1 2026	GRCE Grace Therapeutics	-$0.22	-$0.21	+$0.01	-$0.21	N/A	N/A
6/20/2025	Q4 2025	GRCE Grace Therapeutics	-$0.23	-$0.21	+$0.02	$0.01	N/A	N/A
5/19/2025	Q1 2025	HYPD Hyperion DeFi	-$7.20	-$1.59	+$5.61	-$1.59	$1.60 million	$1.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CSCI COSCIENS Biopharma	N/A	N/A	N/A	N/A	N/A
GANX Gain Therapeutics	N/A	N/A	N/A	N/A	N/A
GRCE Grace Therapeutics	N/A	N/A	N/A	N/A	N/A
HYPD Hyperion DeFi	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CSCI COSCIENS Biopharma	N/A	2.88	2.54
GANX Gain Therapeutics	0.09	1.79	2.22
GRCE Grace Therapeutics	N/A	8.87	11.77
HYPD Hyperion DeFi	N/A	0.34	0.34

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CSCI COSCIENS Biopharma	0.73%
GANX Gain Therapeutics	11.97%
GRCE Grace Therapeutics	6.08%
HYPD Hyperion DeFi	25.84%

Insider Ownership

Company	Insider Ownership
CSCI COSCIENS Biopharma	0.10%
GANX Gain Therapeutics	7.18%
GRCE Grace Therapeutics	11.10%
HYPD Hyperion DeFi	10.86%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CSCI COSCIENS Biopharma	20	3.15 million	3.14 million	N/A
GANX Gain Therapeutics	20	35.95 million	27.91 million	Optionable
GRCE Grace Therapeutics	N/A	13.83 million	12.29 million	N/A
HYPD Hyperion DeFi	40	5.60 million	5.00 million	Optionable

CSCI, GANX, HYPD, and GRCE Headlines

Recent News About These Companies

Kinetiq Announces iHYPE Launch with Hyperion DeFi as First Institutional Depositor

August 14 at 10:16 AM | globenewswire.com

Hyperion DeFi, Inc.: Hyperion DeFi Provides Corporate Update and Reports Second Quarter 2025 Financial Results

August 14 at 9:26 AM | finanznachrichten.de

Hyperion DeFi Reports Q2 2025 Financial Results

August 14 at 9:26 AM | msn.com

Hyperion DeFi Provides Corporate Update and Reports Second Quarter 2025 Financial Results

August 13 at 4:01 PM | globenewswire.com

Hyperion DeFi Inc (HYPD) Q2 2025 Earnings Report Preview: What To Look For

August 12 at 6:48 PM | finance.yahoo.com

Hyperion Defi to Report Second Quarter 2025 Results on Wednesday, August 13, 2025

August 8, 2025 | globenewswire.com

Hyperion DeFi (HYPD) versus The Competition Critical Analysis

August 6, 2025 | americanbankingnews.com

Hyperion DeFi (HYPD) & The Competition Critical Review

August 5, 2025 | americanbankingnews.com

Hyperion DeFi purchases additional $5M in HYPE for Kinetiq iHYPE strategy

July 28, 2025 | msn.com

Hyperion DeFi Purchases Additional $5 Million in HYPE for Kinetiq iHYPE Strategy

July 28, 2025 | globenewswire.com

Hyperion DeFi to Host Corporate Update Event to Discuss Strategic Evolution from Eyenovia and the Future of On-Chain Finance on July 29, 2025

July 17, 2025 | globenewswire.com

Hyperion DeFi, Inc.: Hyperion DeFi Adds $5 Million in HYPE to its Treasury Holdings

July 16, 2025 | finanznachrichten.de

Hyperion DeFi Adds $5 Million in HYPE to its Treasury Holdings

July 15, 2025 | manilatimes.netM

Hyperion DeFi Adds $5 Million in HYPE to its Treasury Holdings

July 14, 2025 | globenewswire.com

Hyperion DeFi stock soars after company rebrands from Eyenovia

July 2, 2025 | uk.investing.com

Eyenovia COO Kern Leaves as Part of Workforce Reduction

July 2, 2025 | marketwatch.com

Eyenovia Announces Rebranding and Corporate Name Change to Hyperion DeFi, Inc.

July 2, 2025 | taiwannews.com.twT

Eyenovia, Inc. Rebrands to Hyperion DeFi, Inc. and Announces Nasdaq Trading Under “HYPD” Ticker

July 2, 2025 | quiverquant.comQ

Eyenovia Adds $10 Million in HYPE to its Treasury Holdings in Preparation for Strategic Onchain Engagement

June 30, 2025 | finance.yahoo.com

Eyenovia Announces Co-Branded Validator with Kinetiq

June 25, 2025 | tmcnet.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CSCI, GANX, HYPD, and GRCE Company Descriptions

COSCIENS Biopharma NASDAQ:CSCI

$3.48 -0.08 (-2.36%)

Closing price 08/14/2025 03:41 PM Eastern

Extended Trading

$2.48 -1.00 (-28.62%)

As of 08/14/2025 07:05 PM Eastern

COSCIENS Biopharma Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.

Gain Therapeutics NASDAQ:GANX

$1.54 -0.01 (-0.65%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$1.54 -0.01 (-0.32%)

As of 08/14/2025 07:46 PM Eastern

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

Grace Therapeutics NASDAQ:GRCE

$3.08 -0.20 (-6.10%)

As of 08/14/2025 04:00 PM Eastern

Grace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.

Hyperion DeFi NASDAQ:HYPD

$6.69 -0.35 (-4.97%)

As of 08/14/2025 04:00 PM Eastern

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time